chris storgard  ardea biosciences  inc  zoominfocom   chris m storgard  rochester mn  intelius sign in we found chris m storgard in rochester mn chris m storgard intelius found that chris m storgard from rochester mn we have connected them to  addresses  phones and  relative or associate get report now chris has lived in rochester mn san diego ca cambridge ma chriss relatives melinda storgard chris m storgard professional status physician rheumatology at mayo clinic get report now want to know more about chris get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about chris or use our people search engine to find others get background check on chris m storgard get a criminal check on chris m storgard get a public record report on chris m storgard get a people search report on chris m storgard chris m storgards contact information known cities lived in find out where chris m storgard has lived as well as chris m storgards phone numbers and email addresses chris m storgard has lived in  states minnesota address for chris m storgard   s s rochester mn has lived in rochester mn san diego ca get full address report phone numbers associated with chris m storgard    rochester mn    cambridge ma get full phone report email addresses associated with chris m storgard cdnet ssedu cdcom get email report chris m storgards education information known schools attended learn about chris m storgards academic history find out which schools chris m storgard attended the dates attended as well as the degrees chris m storgard received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act chris m storgard has attended  schools scripps center for integrative medicine  – 7 chris m storgard has a fellowship in rheumatology scripps center for integrative medicine  – 7 chris m storgard has a fellowship rheumatology in rheumatology university of saskatchewan  –  chris m storgards professional information information regarding chris m storgards professional history find out previous places chris m storgard has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act chris m storgard has worked at  places company mayo clinic title physician rheumatology company fate therapeutics inc title cmo chris m storgards experience title physician rheumatology company mayo clinic job details company size  bil and above  employee range  to less than  title cmo company fate therapeutics inc job details additional professional information on chris m storgard see chris m storgards linkedin profile chris m storgards social network and potential email matches find out potential social network profiles and potential email usernamed for chris m storgard chris m storgards known social networks and potential email matches find all of chris m storgards social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches chris storgard username matches chrisstorgard storgardchris chrisstorgard storgardchris chrisstorgard storgardchris chrisstorgard storgardchris cstorgard popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches c storgard intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   – 07 peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here ardea biosciences  about us management team skip to content about us  management team contact us news  careers  job search view all jobs post resume member login view all jobs working at ardea benefits diversity location search ardea biosciences about us page sub navigation management team contact us page path breadcrumb home about us management team management team james mackay phdpresident  chief operating officer dr mackay joined ardea biosciences in 0 when astrazeneca acquired the san diego based biotech company dr mackay took over the role of president and chief operating officer in 0 dr mackay has been instrumental to setting up an innovative model for ardea biosciences that has retained the biotech’s independence and accountability for the development of the gout franchise whilst also developing a synergistic and collaborative relationship with astrazeneca prior to joining ardea biosciences dr mackay was global product vice president for onglyzakombiglyze xr at astrazeneca and played a critical role in the successful development of the astrazenecabristolmyers squibb diabetes alliance dr mackay has a bs in genetics and phd in medical genetics from aberdeen university scotland jeanluc girardet phdvice president pharmaceutical  translational sciences dr girardet joined the ardea biosciences team in january 7 as senior director of discovery logistics he was promoted to the position of vice president research operations in october 7 and became responsible for all of the company’s drug discovery programs after the selection of ardea’s development compound rdea70 in  his responsibilities have focused primarily on chemistry  development support prior to joining ardea dr girardet served as associate director of chemistry and hiv project team leader at valeant pharmaceuticals in this role he was in charge of selecting and advancing hiv nnrti development candidates as well as leading the process chemistry group in these functions he was instrumental to bringing vrx06 and vrx currently known as rdea06 and rdea into clinical development dr girardet joined valeant in  as part of its acquisition by ribapharm prior to ribapharm dr girardet had worked in the chemistry group at icn pharmaceuticals he earned a phd in organic chemistry from the university of montpellier france and completed postdoctoral studies at the university of michigan ann arbor he is a coauthor of more than 0 scientific publications and book chapters and he holds more than  issued us patents john p montana pmpvice president project management  finance mr montana joined ardea biosciences in november  and is responsible for project leadership project management and strategic planning prior to joining ardea mr montana was the vice president of portfolio management at anadys pharmaceuticals with accountability to the ceo and board of directors for management of the development portfolio and budget from january  until june 6 mr montana was executive director and head of project management at pfizer la jolla labs as a member of the executive leadership team mr montana was responsible for a portfolio of over  development projects including sunitinib sutent® a multikinase inhibitor filed in 6 and currently approved for use in lifethreatening oncology indications prior to pfizers acquisition of the warnerlambert company mr montana was a project leader and manager at agouron pharmaceuticals inc a division of the warnerlambert company since  mr montana joined agouron in  and was involved in both oncology and infectious disease projects including nelfinavir viracept® a protease inhibitor approved for the treatment of hiv mr montana also spent eight years at genetic systemssanofi prior to agouron and was actively involved in the development and registration of blood screening diagnostic products including one of the first rapid tests developed for hiv he holds a bs in microbiologyimmunology from the university of washington and is pmp certified kristin martinvice president human resources facilities  it ms martin joined ardea biosciences in may 0 as the executive director of human resources prior to joining ardea ms martin held senior human resources roles at vantiv in cincinnati ohio and amylin pharmaceuticals in san diego california and cincinnati ohio ms martin has over  years of human resources experience across multiple industries the majority of her career has been in the life sciences industry working with research and development as well as commercial operations and pharmaceutical manufacturing ms martin received her bachelor’s degree from bowling green state university in ohio terms of use privacy policy site map about us news careers contact us  ardea inc 0 fate therapeutics appoints chris m storgard md as chief medical officer  thestreet action alerts plus access aapjim cramers best stocks for 07charitable trust portfoliomost recent trade alert investing rules0 trading commandments real money access rm rules of investingjim cramers best stocks for 070 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 6 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under 0 top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street fate therapeutics appoints chris m storgard md as chief medical officer globenewswire may 7 06 0 am edt san diego may 7 06 globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that chris m storgard md has joined the company as its chief medical officer  dr storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization  as cmo he will lead the design and execution of the companys clinical trials for its programmed cellular immunotherapies we are very pleased to welcome chris during this exciting time for the company as we work to deliver the significant promise of our adoptive immunotherapy programs said scott wolchko president and chief executive officer of fate therapeutics chris brings extensive global clinical trial design and execution leadership to our organization positioning us for success as we launch our phase  clinical trial of protmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic dr storgard has more than 0 years of experience in clinical drug development most recently serving as an integral member of the executive team at ardea biosciences a member of the astrazeneca group  as vice president of clinical research and development at ardea dr storgard led the zurampic® global clinical program to successful us and european regulatory approvals i am excited to be joining the team at fate therapeutics at this pivotal point in the companys evolution as we seek to rapidly and efficiently drive the clinical development of multiple groundbreaking immunotherapies said dr storgard it is a privilege to provide strategic and operational leadership to guide the advancement of novel therapies with the potential to address significant unmet medical needs and transform outcomes for millions of patients with cancer and autoimmune disorders if you liked this article you might like the setup is good for a bounce but it hasnt happened yet some small names are interesting but moreaggressive position trades are not developing right now rev shark mar 0 07  pm est  small biotechs with insider buying insiders have an edge in this complex sector so its worth checking them out bret jensen dec  06 0 am est on the hunt for holiday movers im still bullish but im looking over my shoulder to see if there are some bears sneaking up rev shark nov  06  pm est rotation is the name of the game traders are also looking for smallercaps that can move big around the holiday rev shark nov  06  pm est trending how amazon billionaire jeff bezos gained vast riches and a tech giant someday worth  trillion jim cramer nails starbucks big decline warns again of downside to  heres why snaps stock could be in for another big plunge on monday teslas model  arrives on friday  heres everything you need to know about this overhyped ride ipod nano shuffle are dead here are  other discontinued apple products advertising partners 607 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers chris storgard md  fate therapeutics fate therapeutics management chris storgard md dr storgard is the chief medical officer at fate therapeutics and is leading the company’s clinical development efforts dr storgard has more than 0 years of clinical research and pharmaceutical experience spanning from preclinical to phase iv development previously dr storgard was the vice president clinical research and development at ardea biosciences a member of the astrazeneca group where he led the global clinical development of zurampic® to successful us and european regulatory approvals before joining ardea he held senior positions in drug development and medical affairs at prometheus laboratories biogen idec and amgen where he focused on biologic and small molecule development programs within the inflammation and oncology teams dr storgard holds his md from the university of saskatchewan he completed a fellowship in rheumatology at scripps clinic and research center and served as senior associate consultant division of rheumatology and assistant professor and member of the molecular medicine program at the mayo school of medicine mayo clinic in minnesota menu about us our mission our cells of interest management board of directors pipeline overview immunooncology candidates fatenk engineered hncd6ink engineered car it cell immunoregulation candidates protmune™ toleracyte™ science ex vivo cell modulation ipsc product platform isscr annual meeting and presentations isscr 06 annual meeting collaborations join our team career opportunities vision mission values working at fate investors overview press releases events  presentations financials  filings sec filings annual reports and proxies corporate governance stock information historical stock lookup investors faqs contact fate therapeutics appoints storgard as chief medical officer  san diego business journal san diego business journal home news print email fate therapeutics appoints storgard as chief medical officer by brittany meiling tuesday may 7 06 tweet     chief medical officer dr chris storgard of fate therapeutics san diego’s fate therapeutics inc has appointed a new chief medical officer in charge of clinical trial design and execution the company announced tuesday dr chris m storgard joined fate therapeutics from san diegobased ardea biosciences inc an astrazeneca company where he was vice president of clinical research and development storgard led global clinical trial programs for the astrazeneca drug zurampic which later passed regulatory approval in the us and europe at fate storgard will lead the company’s programmed cellular immunotherapy clinical trials including its lead product candidate protmune “chris brings extensive global clinical trial design and execution leadership to our organization positioning us for success as we launch our phase  clinical trial of protmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic” said scott wolchko president and ceo of fate therapeutics in a statement before joining ardea in 0 storgard held senior positions in drug development and medical affairs at prometheus laboratories inc biogen inc and amgen inc where he focused on biologic and small molecule development programs within the inflammation and oncology teams according to a fate news release storgard holds his md from the university of saskatchewan he also completed a fellowship in rheumatology at scripps clinic and research center fate therapeutics nasdaq fate a thinly traded public company with a market cap of about  million is currently trading for  per share you may also like fate therapeutics raises 0 million astrazeneca to acquire biotech in 6b deal astrazeneca to acquire local biotech for 6b oncosec medical makes appointment to its scientific advisory board retrophin brings on exardea executive to lead rd fate therapeutics ceo christian weyer resigns scott wolchko named successor jerome zeldis named cmo at sorrento therapeutics ardea biosciences to close lay off  employees   home lists finance healthcare manufacturing real estate services technology defense travelleisure browse more classified the lists archives poll archive learn more about us privacy policy contact us edit profile services subscription center online loginregister advertise with us signup for enews updates retailnewsstand locations tools calendar robert half jobs search other journals los angeles business journal orange county business journal san fernando valley business journal  07 san diego business journal phone 776 los angeles business journal orange county business journal san fernando valley business journal san diego business journal     subscribe print edition renewals edit your subscription account email news updates rss headlines feed advertise online display ads business marketplace supplements ascent events sd business events the lists the book of lists resources supplements webconnect marketplace ascent email news updates rss headlines feed robert half jobs search about us sdbj staff privacy policy contact us newsstand locations edit profile login fate therapeutics appoints chris m storgard m d as chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km0  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       fate therapeutics fate appoints chris m storgard md as chief medical officer tweet 706 0 am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs san diego may 7 06 globe newswire  fate therapeutics inc nasdaqfate a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders today announced that chris m storgard md has joined the company as its chief medical officer dr storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization as cmo he will lead the design and execution of the company’s clinical trials for its programmed cellular immunotherapies “we are very pleased to welcome chris during this exciting time for the company as we work to deliver the significant promise of our adoptive immunotherapy programs” said scott wolchko president and chief executive officer of fate therapeutics “chris brings extensive global clinical trial design and execution leadership to our organization positioning us for success as we launch our phase  clinical trial of protmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic” dr storgard has more than 0 years of experience in clinical drug development most recently serving as an integral member of the executive team at ardea biosciences a member of the astrazeneca group as vice president of clinical research and development at ardea dr storgard led the zurampic® global clinical program to successful us and european regulatory approvals “i am excited to be joining the team at fate therapeutics at this pivotal point in the company’s evolution as we seek to rapidly and efficiently drive the clinical development of multiple groundbreaking immunotherapies” said dr storgard “it is a privilege to provide strategic and operational leadership to guide the advancement of novel therapies with the potential to address significant unmet medical needs and transform outcomes for millions of patients with cancer and autoimmune disorders” before joining ardea in 0 dr storgard held senior positions in drug development and medical affairs at prometheus laboratories biogen idec and amgen where he focused on biologic and small molecule development programs within the inflammation and oncology teams dr storgard holds his md from the university of saskatchewan he also completed a fellowship in rheumatology at scripps clinic and research center and served as senior associate consultant division of rheumatology and assistant professor and member of the molecular medicine program at the mayo school of medicine mayo clinic in minnesota in connection with dr storgard’s appointment the company granted dr storgard an option to purchase  shares of the company’s common stock with an exercise price equal to  the closing price per share of the company’s common stock as reported by nasdaq on the effective date of grant may 6 06 which was the date dr storgard’s employment began the option is a nonqualified stock option and vests over a period of four years with  percent vesting on the one year anniversary of the grant date and the remaining 7 percent in approximately equal monthly increments over the succeeding thirtysix months subject to dr storgard’s continuous employment through each vesting date this award was granted as an inducement material to dr storgard’s entering into employment with the company in accordance with nasdaq listing rule 6c and was granted pursuant to the fate therapeutics inc inducement equity plan the company has reserved an aggregate of  shares of its common stock including the shares underlying the option granted to dr storgard for issuance under the inducement equity plan which was approved by the company’s board of directors on may 0 06 about fate therapeutics inc fate therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders the company’s cell therapy pipeline is comprised of immunooncology programs including offtheshelf nk and tcell cancer immunotherapies derived from engineered induced pluripotent cells and immunoregulatory programs including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity its adoptive cell therapy programs are based on the company’s novel ex vivo cell programming approach which it applies to modulate the therapeutic function and direct the fate of immune cells fate therapeutics is headquartered in san diego ca for more information please visit wwwfatetherapeuticscom forwardlooking statements this release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements regarding the company’s advancement of and plans related to the company’s product candidates and research and development programs these and any other forwardlooking statements in this release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements these risks and uncertainties include but are not limited to the risk that the company may cease or delay preclinical or clinical development activities for any of its existing or future product candidates for a variety of reasons including requirements that may be imposed by regulatory authorities and requirements for regulatory approval difficulties or delays in patient enrollment in current and planned clinical trials and any adverse events or other negative results that may be observed during preclinical or clinical development for a discussion of other risks and uncertainties and other important factors any of which could cause our actual results to differ from those contained in the forwardlooking statements see the risks and uncertainties detailed in the company’s periodic filings with the securities and exchange commission including but not limited to the company’s most recently filed periodic report and from time to time the company’s other investor communications fate therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forwardlooking statements contained in this release as a result of new information future events or otherwise contact jesse baumgartner stern investor relations inc 6 jessesternircom read at biospacecom related news fate therapeutics fate announces preclinical data highlighting persistent effector function of allogeneic natural killer cell cancer immunotherapy another director accounting firm quit navidea navb lender tried to freeze its bank accounts fate therapeutics fate reports first quarter 06 financial results facebooks oculus rift developer resigns to work on wearable mri startup fate therapeutics fate to webcast conference call reporting first quarter 06 financial results on may  06 meet the man whose biotech is trying to bring people back from the dead fate therapeutics fate to present preclinical data for protmune at 06 bmt tandem meetings pernix ptx ceo steps down effectively immediately fate therapeutics fate announces fda clearance of investigational new drug application for protmune for prevention of acute gvhd and cmv infection theranos coo abruptly resigns company adds new board members please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • fate therapeutics   • biotechpharma  personnel